Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Jindřich Špinar et al.|New England Journal of Medicine|2021Cited by 4.6k
Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registryJosé López‐Sendón, Teresa López‐Fernández, Carlos Álvarez-Ortega et al.|European Heart Journal|2020Cited by 282
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D. Anker, Giuseppe Rosano, Muhammad Usman et al.|European Journal of Heart Failure|2023Cited by 187
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135
Characterization of Atrial Substrate to Predict the Success of Pulmonary Vein Isolation: The Prospective, Multicenter MASH‐AF II (Multipolar Atrial Substrate High Density Mapping in Atrial Fibrillation) StudyMarco Bergonti, Andrea Sarkozy, Francesco Raffaele Spera et al.|Journal of the American Heart Association|2022Cited by 37